Gabather AB (SE:GABA)
:GABA
Top Page
Gabather AB
(GABA)
Select Model
Select Model
Rating:46Neutral
Price Target:
kr0.04
▲(36.67% Upside)
Action:ReiteratedDate:04/02/26
The score is primarily constrained by weak financial performance: no revenue, negative equity, and ongoing cash burn that implies funding risk. Technicals are relatively neutral with modest positive momentum, but valuation remains unattractive/unclear due to ongoing losses and the absence of a dividend.
Positive Factors
Zero reported debt
The company reports no debt, which materially lowers fixed financing obligations and bankruptcy risk. For a pre-revenue drug developer this durable structural feature preserves strategic optionality for R&D financing, giving management flexibility in capital structure choices.
Negative Factors
Pre-revenue with persistent cash burn
The company remains pre-commercial with no reported revenue and sustained negative operating and free cash flow. Over the medium term this necessitates recurring external funding, increasing dilution or financing risk and making long-term product investment contingent on capital access.
Read all positive and negative factors
Positive Factors
Negative Factors
Zero reported debt
The company reports no debt, which materially lowers fixed financing obligations and bankruptcy risk. For a pre-revenue drug developer this durable structural feature preserves strategic optionality for R&D financing, giving management flexibility in capital structure choices.
Read all positive factors
Gabather AB (GABA) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr21.04M
Dividend YieldN/A
Average Volume (3M)488.51K
Price to Earnings (P/E)―
Beta (1Y)1.51
Revenue GrowthN/A
EPS Growth72.30%
CountrySE
Employees3
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)0.00
Shares Outstanding491,634,160
10 Day Avg. Volume541,248
30 Day Avg. Volume488,507
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)-6.10
Price to Sales (P/S)0.00
P/FCF Ratio-0.73
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Gabather AB Business Overview & Revenue Model
Company Description
Gabather AB (publ) develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, includin...
How the Company Makes Money
null...
Gabather AB Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
12
Very Negative
Cash Flow
7
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -4.53M | 0.00 | 37.00K | -8.55M | -16.99M |
| Net Income | -4.65M | -7.75M | -9.44M | -8.54M | -17.00M |
Balance Sheet | |||||
| Total Assets | 3.83M | 1.83M | 7.36M | 6.75M | 15.39M |
| Cash, Cash Equivalents and Short-Term Investments | 3.14M | 878.00K | 1.11M | 6.27M | 14.85M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 4.69M | 6.01M | 6.88M | 3.31M | 4.43M |
| Stockholders Equity | -863.00K | -4.17M | 486.00K | 3.44M | 10.96M |
Cash Flow | |||||
| Free Cash Flow | -7.22M | -3.33M | -11.64M | -9.60M | -16.12M |
| Operating Cash Flow | -7.22M | -3.33M | -11.64M | -9.60M | -16.12M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financing Cash Flow | 9.49M | 3.09M | 6.49M | 1.02M | 46.00K |
Gabather AB Technical Analysis
Neutral
0.03
Price Trends
0.04
Positive
0.03
Positive
0.04
Positive
Market Momentum
<0.01
Positive
47.78
Neutral
23.09
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:GABA, the sentiment is Neutral. The current price of 0.03 is below the 20-day moving average (MA) of 0.05, below the 50-day MA of 0.04, and below the 200-day MA of 0.04, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 47.78 is Neutral, neither overbought nor oversold. The STOCH value of 23.09 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SE:GABA.
Gabather AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | kr631.18M | -60.92 | -48.65% | ― | -60.33% | 58.04% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | kr275.00M | -3.17 | -530.21% | ― | ― | 17.42% | |
46 Neutral | kr21.04M | -1.13 | ― | ― | ― | 72.30% | |
44 Neutral | kr169.50M | -4.22 | -90.66% | ― | ― | 15.74% | |
43 Neutral | kr85.69M | -2.13 | -24.83% | ― | ― | ― | |
41 Neutral | kr30.66M | -1.77 | ― | ― | ― | ― |
* Healthcare Sector Average
SE:GABA
Gabather AB
0.04
<0.01
13.51%
SE:ALZCUR
AlzeCure Pharma AB
1.48
-0.89
-37.63%
SE:VIVE
Vivesto AB
0.08
-0.13
-62.07%
SE:KLAR
Klaria Pharma Holding AB
1.12
-0.07
-5.57%
SE:NANEXA
Nanexa AB
3.84
2.69
233.48%
SE:ERMA
Enorama Pharma AB
0.41
-2.05
-83.29%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.